Cell and Gene Therapy Answers: The critical role of biomarkers and analytical testing in adoptive cell therapies

Adoptive cell therapies have shown great promise in treating certain cancers. As more and more adoptive cell therapies move toward regulatory approval, robust analytical testing and biomarker identification will be key to delivering the full potential of these life-changing treatments. We spoke with Akanksha Gupta, PhD, executive director for cell and gene therapy at Labcorp, to learn more about the latest advancements and remaining considerations in this rapidly evolving field.

UK-REACH Planning

Advancing your global companion diagnostics program: Insights from a recent Japan symposium (Part 1)

Through companion diagnostics (CDx), a patient can receive individualized treatment designed to improve clinical outcomes while avoiding adverse effects. A key component of precision medicine, CDx can also lead to significant cost savings, cutting up to 60% of the total clinical trial research and development costs. The global CDx market thus has been growing rapidly and is estimated to reach USD 17.6 billion by 2027. It is crucial for companies developing CDx programs to choose a partner with the right capabilities and experience, especially with validations required for approval from regulatory bodies, such as the FDA. Our experience supporting successful CDx clinical trials globally has helped us gain deep insights into CDx development best practices.

Graphical Summary: ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results

Society of Toxicology (SOT) 2024

Labcorp to Announce Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

BURLINGTON, N.C. , Jan. 16, 2024 /PRNewswire/ --  Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter and full year 2023 before the market opens on Thursday, February 15, 2024 .